According to the new market research report Liquid Biopsy Market worth USD 2,047.9 Million by 2022, at a CAGR of 23.4%.

The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

Objectives of the Study

To define, describe, and forecast the global market on the basis of product, clinical application, application, end user, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to four main regions (along with countries), namely, North America, Europe, Asia Pacific, and the Rest of the World
To profile key players and comprehensively analyze their market shares and core competencies
To track and analyze competitive developments such as acquisitions, product developments, partnerships, agreements, expansions, and collaborations in the global market

On the basis of product, the liquid biopsy market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market. The increase in basic research and commercial applications of liquid biopsy, increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth.

Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the circulating tumor cells segment is expected to account for the largest share of the liquid biopsy market. The ability for early assessment of patient prognosis and also providing valuable information to make a clinical decision is driving the growth of the CTC segment in the liquid biopsy market.

By clinical application, the therapy selection segment is expected to account fors the largest market share in 2017

By application, the cancer segment is expected to account for the largest market share in 2017

By end user, the reference laboratories segment is expected to account for the largest market share in 2017

Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=13966350

North America is expected to account for the largest share of the liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region

Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=13966350

Market Players
The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Target Audience:

Liquid biopsy system manufacturers, suppliers, and distributors
Research institutes
Physicians and surgeons
Healthcare service providers and clinical research organizations
Market research and consulting firms